Lopinavir pharmacokinetics in COVID-19 patients

Autor: David Boutoille, Gwenaelle Veyrac, Benjamin Gaborit, Emmanuel Canet, François Raffi, Ronan Bellouard, Paul Le Turnier, Berthe Marie Imbert, Raphaël Lecomte, Matthieu Grégoire
Přispěvatelé: The Enteric Nervous System in gut and brain disorders [U1235] (TENS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Centre hospitalier universitaire de Nantes (CHU Nantes), Thérapeutiques cliniques et expérimentales des infections (EA 3826) (EA 3826), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), DCNS Group [Nantes] (DCNS-Nantes), DCNS group, Université de Nantes (UN), NantesU M, Dépôt
Rok vydání: 2020
Předmět:
Male
Microbiology (medical)
2019-20 coronavirus outbreak
Coronavirus disease 2019 (COVID-19)
viruses
[SDV]Life Sciences [q-bio]
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Pneumonia
Viral
Lopinavir
Betacoronavirus
Pharmacokinetics
immune system diseases
Pandemic
Research Letter
MESH: Aged Betacoronavirus* COVID-19 Coronavirus Infections / blood* Coronavirus Infections / drug therapy Cytochrome P-450 CYP3A Inhibitors / administration & dosage Cytochrome P-450 CYP3A Inhibitors / blood Drug Therapy
Combination Female Humans Lopinavir / administration & dosage Lopinavir / blood* Male Middle Aged Pandemics Pneumonia
Viral / blood* Pneumonia
Viral / drug therapy Ritonavir / administration & dosage Ritonavir / blood* SARS-CoV-2
Humans
Medicine
Pharmacology (medical)
Pandemics
Aged
Pharmacology
Ritonavir
biology
SARS-CoV-2
business.industry
COVID-19
virus diseases
Middle Aged
biochemical phenomena
metabolism
and nutrition
biology.organism_classification
Virology
[SDV] Life Sciences [q-bio]
Infectious Diseases
Cytochrome P-450 CYP3A Inhibitors
Drug Therapy
Combination
Female
Coronavirus Infections
business
medicine.drug
Zdroj: Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy, 2020, 75 (9), pp.2702-2704. ⟨10.1093/jac/dkaa195⟩
ISSN: 1460-2091
0305-7453
DOI: 10.1093/jac/dkaa195
Popis: International audience; The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in late 2019. Therapeutic solutions are currently being tested for COVID-19, the SARS-CoV-2-associated pneumonia. Ritonavir-boosted lopinavir is included in the investigational therapies. A recent in vitro study reported that lopinavir inhibits SARS-CoV-2 replication with a 50% effective concentration (EC50) of 16 720 ng/mL.1Here we describe lopinavir pharmacokinetics in COVID-19 patients treated with ritonavir-boosted lopinavir at the Nantes University Hospital, France.
Databáze: OpenAIRE
Externí odkaz: